ClinicalTrials.gg

Program

drotokibart

Also written as “SHR-1819 Injection” and “SHR-1819 injection”.

In Jiangsu HengRui Medicine's pipeline, IL-4Rα. Its studies are mostly in Dermatitis, Atopic · Rhinitis, Allergic, Seasonal · Prurigo, led by Jiangsu HengRui Medicine.

Furthest: phase 3, since Aug 5, 20248 company-led studies, 4 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine84 open or runningphase 3since Aug 5, 2024Aug 22, 2023Dec 2026phase 3 · NCT07688772

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 22, 2023First study: phase 2 study in Moderate to Severe Atopic DermatitisFirst studyNCT06012812 · 79 enrolled · China
  2. Aug 5, 2024Phase 3 study in Prurigo NodularisNCT06554509 · 423 planned · China
  3. Nov 24, 2024Phase 2 study in Children and Adolescents With Moderate-to-severe Atopic DermatitisNCT06713499 · 51 enrolled · China
  4. Jul 21, 2025Phase 2 study in Rhinitis, Allergic, SeasonalNCT07091357 · 108 enrolled · China
  5. Nov 24, 2025Phase 1 study in Dermatitis, AtopicNCT07264335 · 160 enrolled · China
  6. Dec 15, 2025Phase 3 study in Adolescents With Moderate-to-severe Atopic DermatitisNCT07309055 · 201 planned · China
  7. Dec 21, 2025Phase 2 study in Moderate-to-severe Atopic DermatitisNCT07321951 · 201 enrolled · China
  8. Jun 26, 2026Phase 3 study in Rhinitis, Allergic, SeasonalNCT07688772 · 220 enrolled · China

Ahead

  1. Dec 2026Primary completion: phase 3 study in Rhinitis, Allergic, SeasonalNCT07688772
  2. Jun 2027Primary completion: phase 2 study in Moderate-to-severe Atopic DermatitisNCT07321951
  3. Nov 2027Primary completion: phase 3 study in Adolescents With Moderate-to-severe Atopic DermatitisNCT07309055
  4. Oct 2028Primary completion: phase 3 study in Prurigo NodularisNCT06554509

TargetBeta

“IL-4Rα”the company's pipeline, read by Claude · source

Other programs on IL4R

ProgramCompanyFurthest phaseStudies
dupilumabruleSanofiphase 493
TQH2722Sino Biopharmaceuticalphase 37
SHR-1819Jiangsu HengRui Medicinephase 35

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07688772Rhinitis, Allergic, Seasonal · China3Active, not recruitingDec 2026220
NCT07321951Moderate-to-severe Atopic Dermatitis · China2Active, not recruitingJun 2027201
NCT07309055Adolescents With Moderate-to-severe Atopic Dermatitis · China3RecruitingNov 2027201
NCT07264335Dermatitis, Atopic · China1CompletedJun 26, 2026160
NCT07091357Rhinitis, Allergic, Seasonal · China2CompletedDec 1, 2025108
NCT06713499Children and Adolescents With Moderate-to-severe Atopic Dermatitis · China2CompletedNov 22, 202551
NCT06554509Prurigo Nodularis · China3RecruitingOct 2028423
NCT06012812Moderate to Severe Atopic Dermatitis · China2CompletedJun 5, 202579

How it is read

Names in the registry

  • “SHR-1819 Injection”, 6 entries
  • “SHR-1819 injection”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.